2017
Leaving a legacy of stroke in Europe: A community of dedicated professionals is changing the face of stroke in Europe
MIKULÍK, Robert, Pauli YLIKOTILA, Risto ROINE, Miroslav BROZMAN, Sandy MIDDLETON et. al.Základní údaje
Originální název
Leaving a legacy of stroke in Europe: A community of dedicated professionals is changing the face of stroke in Europe
Autoři
MIKULÍK, Robert (203 Česká republika, garant, domácí), Pauli YLIKOTILA (246 Finsko), Risto ROINE (246 Finsko), Miroslav BROZMAN (703 Slovensko) a Sandy MIDDLETON (36 Austrálie)
Vydání
Oruen - The CNS Journal, [S.l.], Oruen Limited, 2017, 2059-2442
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30200 3.2 Clinical medicine
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Kód RIV
RIV/00216224:14110/17:00099249
Organizační jednotka
Lékařská fakulta
Klíčová slova anglicky
acute stroke; door-to-needle; FeSS protocols; QASC
Štítky
Příznaky
Recenzováno
Změněno: 19. 3. 2018 18:30, Soňa Böhmová
Anotace
V originále
Time is of the essence in the treatment of acute stroke; however, there are wide variations, across and within countries, in the ability to hospitalize, scan, diagnose, and treat acute stroke patients rapidly within the accepted time window of 4.5 hours. Door-to-needle (DTN) time is an important performance indicator that illustrates the speed and operational efficiency of stoke units. Significant progress is being made; DTNs often exceeded an hour only a few years ago, but can now be achieved in under seven minutes in leading stroke units. This symposium examined the strategies and contributory factors that result in reduced DTN times, and how these strategies can be more widely implemented. The Quality in Acute Stroke Care (QASC) programme in Australia has shown the incorporation of standardized nurse-led treatment protocols for the management of fever, hyperglycaemia, and dysphagia (FeSS protocols) significantly improve outcomes for stroke patients. European evaluation of these protocols, in collaboration with ESO and the ANGELS initiative, and potentially leading to their adoption in European acute stroke treatment practice is discussed.